Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12883530 | 0.91 | KDM4E (0.38) | KDM4ETDP1CYP2A6MMP3ENPP2 | |
| SCHEMBL4756404 | 0.89 | KDM4E (0.37) | KDM4ETDP1CYP2A6MMP3ENPP2 | |
| SCHEMBL4007007 | 0.86 | KDM4E (0.52) | KDM4ETDP1MMP3ENPP2MEN1 | |
| SCHEMBL21300469 | 0.85 | ALDH1A1 (0.35) | KDM4ETDP1CYP2A6MMP3ENPP2 | |
| SCHEMBL25371047 | 0.84 | KDM4E (0.34) | KDM4ETDP1CYP2A6MMP3ALDH1A1 | |
| SCHEMBL30694818 | 0.84 | KDM4E (0.34) | KDM4ETDP1CYP2A6MMP3 | |
| SCHEMBL30694807 | 0.84 | KDM4E (0.34) | KDM4ETDP1CYP2A6MMP3ALDH1A1 | |
| SCHEMBL25370593 | 0.84 | KDM4E (0.34) | KDM4ETDP1CYP2A6MMP3 | |
| SCHEMBL7196848 | 0.81 | ENPP2 (0.53) | KDM4ETDP1CYP2A6MMP3ENPP2 | |
| SCHEMBL2600192 | 0.79 | CYP2A6 (0.58) | KDM4ETDP1CYP2A6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100422160-C | Morpholine derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2008-10-01 | — | — | CN | disclosed |
| EP-1150970-B1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI AVENTIS (FR) | 2007-08-22 | — | — | EP | disclosed |
| CN-1273463-C | (1-phenacyl-3-phenyl-3-piperidinylethyl) piperidine derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2006-09-06 | — | — | CN | disclosed |
| US-6951940-B2 | Piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2005-10-04 | — | — | US | disclosed |
| EP-1165528-B1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-09-01 | — | — | EP | disclosed |
| US-20040072840-A1 | Novel piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | US | disclosed |
| US-6642233-B1 | Strong affinity and high selectivity for the human NK1 receptors of substance P. | SANOFI-SYNTHELABO (FR) | 2003-11-04 | — | — | US | disclosed |
| US-6506750-B1 | N-(phenylacetyl)morpholine derivatives useful as NK1 receptor antagonists, a process for the preparation thereof, and pharmaceutical compositions containing them as active principle. | SANOFI-SYNTHELABO (FR) | 2003-01-14 | — | — | US | disclosed |
| CN-1353698-A | Novel morpholine derivatives, method for production thereof and pharmaceutical preparations containing said derivatives | SANOFI SYNTHELABO (FR) | 2002-06-12 | — | — | CN | disclosed |
| CN-1345317-A | (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for production thereof and pharmaceutical compositions containing the same | SANOFI SYNTHELABO (FR) | 2002-04-17 | — | — | CN | disclosed |
| EP-1165528-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058292-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072840-A1 | Novel piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them | TACR1, TACR2, KCNJ11 | KDM4E 1930/4885TDP1 2849/4885CYP2A6 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.